Xlife Sciences
Update in progressXLS.SW (Swiss)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Xlife Sciences AG develops and commercializes life sciences projects across technology platforms, biotechnology/therapies, medical devices, and AI/digital health. The company identifies new therapies and biomarkers from human genetic data, manufactures active pharmaceutical ingredients for humans and animals, and offers clinical research services. It bridges R&D with healthcare markets, supports researchers and entrepreneurs, and pursues kidney-disease biomarkers, antibody-drug conjugates, microfluidic antibody screening, and Neuromex for early neurological disease detection.Founded in 2019, based in Zurich, Switzerland.
Company score
- Sentiment
- 0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- 0.21
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketSwiss (EBS)
- LocationSwitzerland
- CEOMr. Oliver R. Baumann
- Founded2019
- Employees20
- Websitewww.xlifesciences.ch
Identifiers
- ISINCH0461929603
- FIGIBBG0157TVP42
- LEI984500AH590BE88BB517